Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
| Revenue (TTM) | $228.37M |
| Gross Profit (TTM) | $170.21M |
| EBITDA | $47.44M |
| Operating Margin | 22.70% |
| Return on Equity | 28.00% |
| Return on Assets | 10.80% |
| Revenue/Share (TTM) | $4.57 |
| Book Value | $2.59 |
| Price-to-Book | 2.93 |
| Price-to-Sales (TTM) | 1.68 |
| EV/Revenue | 1.371 |
| EV/EBITDA | 5.87 |
| Quarterly Earnings Growth (YoY) | -34.40% |
| Quarterly Revenue Growth (YoY) | 27.70% |
| Shares Outstanding | $50.88M |
| Float | $39.01M |
| % Insiders | 15.63% |
| % Institutions | 72.88% |
Volatility is currently contracting